cheap prom dresses prom dresses, cheap wedding dresses cheap wedding dresses, vintage wedding dresses vintage wedding dresses, cheap prom dresses cheap prom dresses for sale.
Top cheap prom dress cheap prom dresses, sexy wedding dresses sexy wedding dresses, prom dresses prom dresses, vintage prom dresses vintage peom dresses on sale.
首页| 关于依普比善| 品类动态| 学术天地| 临床讲座在线| PubMed文献速览| 在线交流| 联系我们
· “依普比善®醋酸奥曲肽注射液诚招全国代理商
· 依普比善®醋酸奥曲肽注射液市场现状及发展规划
· 依普比善®0.05毫克规格获SFDA批准生产
· 依普比善®(醋酸奥曲肽)0.3mg、0.05mg规格特价招商
· 招聘信息
· 0.05mg规格依普比善®变更有效期申请已报北京药监局
· 依普比善®试行标准转正申请进入复核阶段
· 依普比善®---醋酸奥曲肽注射液诚招部分地区地市级代理商
· 供应醋酸奥曲肽原料及水针制剂
· 0.05mg规格依普比善®变更有效期申请已获得北京药监局批准
· 招聘启事
· 依普比善®品牌知识问答
· 2008年消化、肿瘤专业国内学术会议消息
· 依普比善®推荐用法用量
· 依普比善®醋酸奥曲肽注射液与进口品的对比
· 依普比善®市场现状及最新发展规划
· 依普比善®与生长抑素类制剂的比较
· 依普比善®委托北京双鹭药业股份有限公司生产
· 依普比善®最新LOGO公布
· 依普比善®网站的问卷调查
· 生长抑素说明书
· 国家发改委关于生长抑素的最高定价
· 宝依普公司招聘启事
· 依普比善®礼品鼠标垫发放通知
· 《奥曲肽临床研究论文集》-5 发放通知
· 依普比善®“LOGO释义”
· 依普比善®产品图片
· 便签贴发放通知
· 《奥曲肽临床研究论文集》-6 发放通知
· 依普比善®礼品签字笔发放通知
· 依普比善®新包装投放市场通知
· 依普比善®更换新包装相关说明
· 依普比善®新旧包装对比说明
· 依普比善®网刊8及品牌礼品发放通知
· 奥曲肽、生长抑素统一定价药品最高零售限价
· 依普比善®再获商标注册证通告
 
 
   
  PubMed奥曲肽临床文献速览
   


小鼠前列腺神经内分泌肿瘤的抗前列腺癌发展模型中,唑来膦酸不是作为生长抑素类似物发挥抗癌作用(2013.04)
    

Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.

小鼠前列腺神经内分泌肿瘤的抗前列腺癌发展模型中,唑来膦酸不是作为生长抑素类似物发挥抗癌作用

Abstract

 

BACKGROUND:

Since neuroendocrine (NE) cells play an important role in the development of castration-resistant prostate cancer (CRPC), target therapy to NE cells should be considered for treating CRPC. We investigated the effects zoledronic acid (ZOL) and two somatostatin analogs (octreotide: SMS, and pasireotide: SOM) on an NE allograft (NE-10) and its cell line (NE-CS), which were established from the prostate of the LPB-Tag 12T-10 transgenic mouse.

METHODS:

We examined the in vivo effects of ZOL, SMS and SOM as single agents and their combinations on subcutaneously inoculated NE-10 allografts and the in vitro effects on NE-CS cells. Apoptosis and cell cycle activity were assessed by immunohistochemistry using TdT-mediated dUTP-biotin nick-end labeling (TUNEL) and a Ki-67 antibody, respectively.

RESULTS:

In vivo growth of NE-10 tumors treated with ZOL, ZOL plus SMS, or ZOL plus SOM was significantly inhibited compared to the control as a consequence of induction of apoptosis and cell cycle arrest. ZOL induced time- and dose-dependent inhibition of in vitro proliferation of NE-CS cells, but the somatostatin analogs (SMS and SOM) did not. ZOL also inhibited migration of NE-CS cells. These effects were caused by inhibition of Erk1/2 phosphorylation via impairment of prenylation of Ras.

CONCLUSIONS:

ZOL, but not SMS or SOM, induced apoptosis and inhibition of proliferation and migration through impaired prenylation of Ras in NE carcinoma models. Our findings support the possibility that ZOL could be used in the early phase for controlling NE cells, which may trigger progression to CRPC.

 
 
客户服务 | 网站地图 | 在线留言 | 法律声明 | 友情链接 | 站内搜索 | 图片栏目 | 北京宝依普

版权所有 © 2005-2019 北京宝依普生物高技术有限责任公司 Beijing BIOEPO Biopharmaceutical Ltd.
电话:010-68210072 68289602 60216589 联系信箱:epbs@sina.com
京ICP备06033228号